Back
Compare AU
Compare IZZ vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares China Large-Cap ETF (IZZ) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IZZ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 67 |
Median incremental investment | $1,993.50 | $738.73 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,235.00 | $1,951.68 |
Average age group | > 35 | > 35 |
Key Summary
IZZ | DRUG | |
|---|---|---|
Strategy | IZZ.AX was created on 2004-10-05 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to provide investors with the performance of the FTSE China 50 Index, before fees and expenses. The index is designed to measure the performance of 50 of the largest and most liquid Chinese companies which trade on the Hong Kong Stock Exchange | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | TENCENT HOLDINGS LTD (10.00 %) ALIBABA GROUP HOLDING LTD (8.96 %) XIAOMI CORP (7.49 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (59.03 %) Consumer Discretionary (16.54 %) Communication Services (12.68 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | China (100.00 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.74 % | 0.57 % |
Key Summary
IZZ | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | FTSE China 50 Net Tax USD Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.74 % | 0.57 % |
Price | $60.71 | $8.58 |
Size | $519.495 million | $168.713 million |
10Y return | 14.48 % | N/A |
Annual distribution yield (5Y) | 2.26 % | 1.97 % |
Market | ASX | ASX |
First listed date | 15/11/2007 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IZZ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 67 |
Median incremental investment | $1,993.50 | $738.73 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,235.00 | $1,951.68 |
Average age group | > 35 | > 35 |
Pros and Cons
IZZ | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IZZ | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |